In SLE patients positive for STAT4 risk allele, tofacitinib led to a decreased expression of interferon-response genes and low levels of circulating density granulocytes and neutrophil NETosis, as well as to the suppression of pSTAT1 in CD4+ T cells [36]. Here, STAT4 is linked to systemic lupus erythematosus.